CDXS Codexis, Inc.

NASDAQ
$1.15

Codexis Delivers a Margin-Led Beat, but Slipping ECO Synthesis Deal Timelines Leave a Sub-$1 Stock Waiting for Proof

Codexis turned in its strongest quarter in some time, and its income statement is improving quickly. The company reported a loss of $0.08 per share, beating the -$0.09 consensus by 11.1%. Revenue of $19.26 million topped the $18.49 million estimate by 4.2% and grew 124.0% year over year. Earnings improved 63.6% from a year ago as the net loss shrank to $8.1 million from $19.6 million. Growth also accelerated sequentially: revenue had been essentially flat at $15.2 million in Q1 and $14.9 million in Q2 before jumping to $19.3 million. The central tension is that the beat comes from the legacy BioCatalysis business, while the investment case still depends on ECO Synthesis commercial contracts that have not yet arrived.

The quality of the quarter is better than a typical small-cap beat. Product revenue more than doubled to $15.7 million from $6.8 million, driven by customer launches of newer, higher-margin enzyme-enabled drugs. Product gross margin expanded to 74.5% from 64% a year ago, continuing a steady climb from 71% in Q1 and 73% in Q2. Management raised its full-year gross margin outlook for the second straight call, to the low-70% range. That is up from a high-60s view in Q2 and an expectation of roughly 64% at the start of the year. Costs fell as well: R&D dropped to $12.6 million and SG&A to $10.1 million, both on lower headcount-related spending.

Two items temper the improvement. First, per-share figures benefited less than absolute losses because weighted shares rose to 107.3 million from 90.3 million, reflecting the roughly $25 million July equity raise. Second, contract assets jumped to $8.6 million from $0.5 million at year-end while deferred revenue fell from $7.0 million to $0.7 million. That pattern suggests a meaningful portion of recognized revenue has not yet been billed or was previously prepaid.

On the call, ECO Synthesis momentum was real but remains pre-commercial. Codexis described several advances:

  • an evaluation agreement with a large biopharma covering ligation for a late-stage, large-indication siRNA asset, which includes its first tech transfer into an innovator's pilot-scale plant;
  • an October feasibility study with an siRNA pioneer;
  • two new CDMO engagements, bringing the total to five;
  • 100-gram batches with more than 90% crude purity and a 40% cycle-time reduction;
  • stereo-defined siRNA showing 3-4x greater potency;
  • what management called a constructive FDA Emerging Technologies meeting.

Management now frames customer discussions as being about deployment rather than curiosity. Commercialization, however, is moving more slowly than promised. The lead CDMO long-term contract, which management hoped in Q2 to finish "fairly quickly," is still in conversations. The 2026 licensing-deal goal has effectively been pushed into 2027, and management called deal timing "very difficult to predict." The 500-gram scale target and the start of GMP construction, previously tied to year-end and the second half of 2026, are now described only as coming "in the coming months." The GMP facility is not expected to be operational until the end of 2027.

The operating risks are not limited to ECO Synthesis. The Phase II/III biocatalysis pipeline shrank from 15 programs to 12. Management also acknowledged that customers are more aggressively evaluating alternative enzymatic technologies. Reaffirming $72-76 million in full-year revenue requires $22.6-26.6 million in Q4, a step up from the record Q3 in a business whose orders are lumpy.

The financing picture improved. The new $60 million Trinity Capital facility refinanced roughly $42 million of debt with 48 months of interest-only payments. Combined with $72.7 million in cash and investments, it supports a reaffirmed runway through 2028 that includes the GMP buildout. The remaining $17.5 million of the facility is available subject to conditions.

The market has not rewarded any of this. Shares closed at $0.98 heading into the report, down 34.5% from the $1.49 open after the August release. They sit 44.7% below the inter-earnings high of $1.77 and just 2.8% above a fresh 52-week low of $0.95 set the day before earnings. The stock is also 45.5% below its 200-day moving average. A sub-$1 price makes the Nasdaq listing-compliance risk cited in the release more than boilerplate. Investor sentiment remains negative but improved notably, rising from -0.34 to -0.18, which suggests expectations had been depressed going in. Price and AVWAP trend readings remain negative, with only momentum turning positive.

The bottom line is that Codexis delivered a genuinely better quarter, with accelerating revenue, rising margins, lower costs and a sturdier balance sheet. Bears still have legitimate ammunition. The deals that would validate ECO Synthesis economically keep slipping, the biocatalysis pipeline thinned, and Q4 guidance demands another step up. Until a long-term CDMO or licensing contract is signed, the improving financials buy time rather than resolve the debate, and the stock's position near its lows shows how little benefit of the doubt investors are extending.

← Back to CDXS news

Read our preview of this report →